New Ranking Method Improves Antiseizure Drug Predictions for Patients
Researchers studied how well different animal models can predict the effectiveness of antiseizure medications (ASMs) for people with focal drug-resistant epilepsy (DRE).
This hub covers epilepsy genetics: how gene changes can contribute to seizures (often in children). We translate studies on testing, results like VUS, and what findings may change for care.
No. It’s common in pediatrics, but adults can benefit from genetic testing, too, especially with unclear diagnosis or family history.
Sometimes. For certain conditions, results can guide medication choice, diet therapies, or referral decisions.
It usually means “not enough evidence yet.” It shouldn’t be treated as a definite cause, but it can be reclassified over time.
Not necessarily. Testing can miss some variants, and new gene links are still being discovered.
Researchers studied how well different animal models can predict the effectiveness of antiseizure medications (ASMs) for people with focal drug-resistant epilepsy (DRE).
This study looked at 177 children with epilepsy and specific genetic changes called copy number variants (CNVs).
Researchers studied infants aged 1 to 24 months who experienced their first seizure without fever or were newly diagnosed with epilepsy.
This study looked at children with a specific genetic condition called YWHAG-associated Neurodevelopmental Disorder (YWHAG-NDD), which can cause seizures and developmental delays.
This study looked at childhood absence epilepsy (CAE), a common type of epilepsy that affects children, particularly those in school.
Researchers studied the relationship between tau protein changes and epilepsy, particularly in adults over 55 years old.
Researchers studied a new way to manage epilepsy by combining different types of information and expertise.
Researchers studied how different parts of the brain communicate in patients with epilepsy, focusing on the areas where seizures start, known as the seizure onset zone (SOZ).
This study looked at patients who started having seizures for the first time during a COVID-19 infection.